Abbott to Split Into Two Separate Companies, Reports Q3 Sales Rise 13 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott today announced that it will split into two separate, publicly-traded companies — one focused on diversified medical products and the other on research-based pharmaceuticals.

The diversified medical products business, which includes the branded generic pharmaceutical, medical devices, diagnostics (including molecular diagnostics), and nutritional businesses, will retain the Abbott name. These businesses combined bring in annual revenues of roughly $22 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Nature News explores the president's "science legacy."

In PLOS this week: genetic factors associated with facial features, a new mutation that makes individuals more prone to Brugada syndrome, and more.

Nutrigenomic companies offer gene-based diet advice, the Wall Street Journal reports.

Researchers have found a new kind of virus — one that starts out broken up into five parts.